Caring for Japan's elderly - Mission impossible?

Lancet

Volumn 352, Issue 9130, 1998, Pages 798-

  Watts, Jonathan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ECONOMICS; ELDERLY CARE; FORECASTING; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; JAPAN;

AGED; FORECASTING; HEALTH CARE COSTS; HEALTH SERVICES FOR THE AGED; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, HEALTH; JAPAN;

EID: 0032486857     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60704-0     Document Type: Article

References (57)

1. Solicia C, Capella C, Buffa R, et al. Endocrine cells of the digestive system. In: Johnson LR (ed). Physiology of the gastroentestinal tract. New York: Raven Press, 1981: 39-58.
2. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; i: 238-39.
3. Goodwin JD. Carcinoid tumours: an analysis of 2837 cases. Cancer 1975; 36: 560-69.
4. Hodgson HJ. Carcinoid tumours and the carcinoid syn drome. In: Bonchier IA, Allan RN, Hodgson HJ, et al (eds). Gastroenterology: clinical science and practice. London: WB Saunders, 1992: 643-58.
5. Kaplan LM. Endocrine tumours of the gastrointestinal tract and pancreas. In: Wilson JD, Braunwald E, Isselbacher KJ, et al (eds). Harrisons principles and practices of internal medicine. New York: McGovern Ine, 1991: 1386-93.
6. Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol 1907; 1: 426-29.
7. Soga J, Tazawa K. Pathologic analysis of carcinoids. Cancer 1971; 28: 990-98.
8. DeLellis RA, Dayal Y, Wolfe HJ. Carcinoid tumours: changing concepts and new perspectives. Am J Surg Pathol L984; 8: 295-300.
9. Black WC. Enterochromaffin cell types and corresponding carcinoid tumours. Lab Invest 1968; 19: 473-76.
10. Norheim I, Norheim-Theodorsson E, Brodin E, Oberg K. Tachykinins in carcinoid tumours: their use as a tumour marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986; 64: 605-12.
11. Lehy T, Mignon M, Cadiot G, et al. Gastric endocrine cell behaviour in Zollinger-Ellison patients on long term potent antisecretory treatment. Gastroenterology 1989; 96: 1029-40.
12. Larsson C, Skogsied B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
13. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science L997; 276: 404-07.
14. Earners CBH, Stadil F, Van Tongren J. Prevalence of endocrine abnormalities in patients with the Zollinger-Ellison syndrome and in their families. Am J Med 1978; 64: 607-12.
15. Dong Q, Debenelenko EV, Chandrasekharappa SC, et al. Loss of heterozygosity at 11q 13: analysis of pituitary tumours, lung carcinoids, lipomas, and other uncommon tumours in subject with familiar multiple endocrine neoplasia type 1. J Clin Endocrinol Melab 1997; 82: 1416-20.
16. Mitchell ME, Johnson JA, Wilton PB. Five primary synchronous neoplasms of the gastroentestinal tract. J Clin Gastroenterol 1996; 23: 284-88.
17. Nagaoka S, Toyoshima H, Bandoh T, et al. Composite carcinoidadenocarcinoma tumour of the stomach. Surg Today 1996; 26: 184-88.
18. Williams IM, Williams NW, Stock D, Foster ME. Collision tumour of the ampulla of Vater: carcinoid and adenocarcinoma. HPB Surg 1997; 10: 241-44.
19. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637-44.
20. Warburton R, Keevil B. Urinary 5-hydroxyindole-acetic acid by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1997; 34: 424-26.
21. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-28.
22. Giovanni M, Seitz JF, Thomas P, et al. Electronic sectorial ultrasound endoscopy in benign and malignant tumoral pathology of the stomach: results in 30 patients. Gastroenterol Clin Biol 1993; 17: 26-32.
23. Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumours: imaging procedures and interventional radiology. World J Surg 1996; 20: 147-56.
24. Aspestrand F, Kolmannskog F, Jacobsen M. CT, MR imaging and angiography in pancreatic apudomas. Acta Radial 1993; 34: 468-73.
25. Vincent JM, Trainer PJ, Reznek RH, et al. The radiological investigation of occult ectopic ACTH-dependent Cushings syndrome. Clin Radial 1993; 48: 11-17.
26. Kwekkeboom DJ, Krenning EP. Somatostatin receptor scintigraphy in patients with carcinoid tumours. World J Surg 1996; 20: 157-61.
27. Hoefnagel CA, den Hartog Jager FCA, Taal BG, et al. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987; 13: 187-91.
28. Kisker O, Bartsch D, Weinel RJ, et al. The value of somatostatinreceptor scintigraphy in newly dianosed endocrine gastroenteropancreatic tumours. J Am Coll Surg 1997; 184: 487-92.
29. Perault C, Schvartz C, Wampach H, et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. J Nucl Med 1997; 38: 1234-42.
30. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumours of the vermiform appendix. Cancer 1968; 21: 270-75.
31. Surveillance Epidemiology and End Results (SEER) Program. Division of cancer prevention and control: National Cancer Institute, 1987.
32. Moertel CG, Sauer WG, Dockerty MB, et al. Life history of the carcinoid tumour in the small intestine. Cancer 196 1; 14: 1901-99.
33. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroentrol 1995; 90: 338-53.
34. Muller J, Kirchner T, Muller-Hermelin k HK. Gastric endocrine cell hyperplasia and carcinoid tumors in atrophie gastritis type A. Am J Surg Pathol 1987; 1: 909-17.
35. Rindi G, Luineti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinopathologic study. Gastroenterology 1993; 105: 1264-66.
36. Rothmund M, Kisker O. Surgical treatment of carcinoid tumours of the small bowel, appendix, colon and rectum. Digestion 1994; 55: 86-91; 104: 994-1006.
37. Dusmet ME, McKneally MF. Pulmonary and thymic carcinoid tumours. World J Surg 1996;20: 189-95.
38. Melmon KL, Sjoerdsma A, Oates JA, Laster L. Treatment of malabsorption and diarrhoea of the carcinoid syndrome with methysergide. Gastoenterology 1965; 48: 18-24.
39. Gustafsen J, Lendorf A, RaskovH, Boesby S. Ketanserin versus placebo in carcinoid syndrome: a clinical control trial. Scand J Gastrenterol 1986; 21: 816-18.
40. Moertel CG, KvolsLK, Rubin J. A study of cyproheptadine in the treatment of meatstatic carcinoid tumour and the malignant carcinoid syndrome. Cancer 1991; 67: 33-36.
41. Platt AJ, Heddle RM, Rake MO, Smedley H. Ondansetron in carcinoid syndrome (letter). Lancet 1992; 339: 1416.
42. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumours: the place of somatostatin analogues. Digestion 1995; 55: 107-13.
43. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-38.
44. Ruszniewski P, Ducreux M , Chayvialle JA, rt al. Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279-83.
45. Oberg K. The use of chemotherapy in the management of neuroendocrine tumours. Endocrinol Metab Clin North Am 1993; 22: 941-52.
46. Oberg K, Eriksson B, Janson ET. Interferons alone in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumours. Digestion 1994; 3: 64-69.
47. Moertel CG, Johnson CM, McKusick Ma, et al. The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 1994; 120: 302-09.
48. Mitty HA, Warner RR, Newman LH, Train JS, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985;155: 623-26.
49. Hajarizadeh H, Ivancev K, Mueller C, et al. Effective palliative treatment of metastatic carcinoid tumours with intra-arterial chemotherapy/chemoembolisation combined with octreotide acetate. Am J Surg 1992; 163:479-83.
50. Marlink RG, Lokich JJ, Robins JR, et al. Hepatic arterial embolization for metastatic hormone-secreting tumours. Cancer 1990; 65: 2227-31.
51. Krenning EP, Valkema P, Kooil PPM, et al Peptide receptor radionuclide therapy with (Indium- 111-DTPA-Phe)-Octreotide. J Nucl Med 1997; 38: 47P.
52. Taal BG, Hoefnagel CA, Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours. J Clin Oncol 1996; 14: 1829-38.
53. Otte A, Mueller-Brand J, Delias S, et al. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998; 351: 417-18.
54. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28: 317-36.
55. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55: 98-103.
56. Le Treut PY, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumours. Ann Surg 1997; 225: 335-64.
57. Moertel CG. Gastrointestinal carcinoid tumours and malignant carcinoid syndrome. In: Kelley WN (ed). Textbook of internal medicine. Philadelphia: Lippincott Co, 1992: 1166-72.